Risk of T2DM and impaired fasting glucose among PCOS subjects: Results of an 8-year follow-up

Current Diabetes Reports

Volumn 6, Issue 1, 2006, Pages 77-83

  Boureaux, Monique Y ^b   Talbott, Evelyn O ^a   Kip, Kevin E ^b   Brooks, Maria M ^b   Witchel, Selma F ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 33645324444     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0056-1     Document Type: Review

References (40)

1. Yen SS: Chronic anovulation caused by peripheral endocrine disorders. In Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, edn 2. Edited by Yen S, Jaffe R. Philadelphia: W.B. Saunders Co.; 1986:576-630.
2. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005, 352:1223-1236.
3. Azziz R, Woods KS, Reyna R, et al.: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
4. Legro RS, Bentley-Lewis R, Driscoll D, et al.: Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002, 87:2128-2133.
5. Kiddy DS, Hamilton-Fairley D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992, 36:105-111.
6. Dunaif A, Scott D, Finegood D, et al.: The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in PCOS. J Clin Endocrinol Metab 1996, 81:3299-3306.
7. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
8. Talbott E, Guzick D, Clerici A, et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995, 15:821-826.
9. Nordt TK, Sawa H, Fujii S, et al.: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770.
10. Talbott E, Clerici A, Berga SL, et al.: Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998, 51:415-422.
11. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al.: Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20:2414-2421.
12. Dunaif A, Graf M, Mandeli J, et al: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65:499-507.
13. Dunaif A, Finegood DT: Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:942-947.
14. Legro RS, Kunselman AR, Dodson WC, et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
15. Weerakiet S, Srisombut C, Bunnag P, et al.: Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001, 75:177-184.
16. Talbott EO, Zborowski JV, Boudreaux MY: Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? A review of the evidence. Minerva Ginecol 2004, 56:27-39.
17. Ehrmann DA, Barnes RB, Rosenfield RL, et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-146.
18. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998.
19. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [no authors listed]. Diabetes Care 1997, 20:1183-1197.
20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
21. Warnick GR, Albers JJ: A comprehensive evaluation of heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978, 19:65-76.
22. Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973, 19:476-482.
23. Fried LP, Borhani NO, Enright P, et al.: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991, 1:263-276.
24. Bondar RJ, Mead DC: Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem 1974, 20:586-590.
25. Matthews DR, Hosker JP, Rudenski AS, et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
26. Bonora E, Targher G, Alberiche M, et al.: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
27. Hanson RL, Pratley RE, Bogardus C, et al.: Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000, 151:190-198.
28. Howard G, Bergman R, Wagenknecht LE, et al.: Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model." Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998, 8:358-369.
29. Hauner H: Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol 2004, 3:223-232.
30. Ovalle F, Azziz R: Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002, 77:1095-1105.
31. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
32. Nelson VL, Qin KN, Rosenfield RL, et al.: The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925-5933.
33. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM: Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999, 13:946-957.
34. Wickenheisser JK, Nelson-DeGrave VL, Quinn PG, McAllister JM: Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol 2004, 18:588-605.
35. Wickenheisser JK, Nelson-Degrave VL, McAllister JM: Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1720-1727.
36. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980, 50:113-116.
37. Dunaif A, Segal KR, Futterweit W, et al.: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
38. Chang RJ, Nakamura RM, Judd HL, et al.: Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983, 57:356-359.
39. dos Reis RM, Foss MC, de Moura MD, et al.: Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism. Gynecol Endocrinol 1995, 9:45-50.
40. Shoupe D, Kumar DD, Lobo RA: Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983, 147:588-592.